Since FOXP3 is crucial for suppressing anti-tumor immunity, clinical validation of FOXP3 and its associated post-translational modification (PMT) proteins could provide potential therapeutic target and prognostic significance for glioma treatment. The gene discussed is FOXP3; the disease is central nervous system cancer.